|Chemical and physical data|
|Molar mass||570.63556 g/mol|
|3D model (Jmol)||Interactive image|
Naldemedine (INN, USAN; S-297,995) is a peripherally-selective μ-opioid receptor antagonist under development by Shionogi for the treatment of opioid-induced adverse effects including constipation, nausea, and vomiting. Clinical studies have thus far found it to possess statistically significant effectiveness for these indications and to be generally well-tolerated with predominantly mild to moderate gastrointestinal side effects.<ref name="Sprawls1997" / No effects indicative of central opioid withdrawal or impact on the analgesic or mydriatic effects of co-administered opioids have been observed. As of July 2014, naldemedine is in phase III clinical trials in the United States and Japan.
- De Sarro, Giovambattista; Kelly S. Sprawls; Egilius L.H. Spierings; Dustin Tran (2012-03-07). "Drugs in Development for Opioid-Induced Constipation" (PDF). In Catto-Smith G., Anthony. Constipation - Causes, Diagnosis and Treatment. p. 7. doi:10.5772/30377. ISBN 978-953-51-0237-3. Retrieved 12 May 2012.
- Shionogi (2009-03-27). "Research and Development at Shionogi (as of March 2009)" (PDF). Retrieved 2012-05-12.
- Nagase H, Fujii H (2011). "Opioids in preclinical and clinical trials". Topics in Current Chemistry. 299: 29–62. doi:10.1007/128_2010_74. PMID 21630515.